生产力
制药工业
收入
业务
医疗保健产业
质量(理念)
产业组织
医疗保健
风险分析(工程)
过程(计算)
计算机科学
生物技术
经济
财务
经济增长
哲学
操作系统
认识论
生物
作者
Steven M. Paul,Daniel S. Mytelka,Christopher T. Dunwiddie,Charles Persinger,Bernard Munos,Stacy Lindborg,Aaron L. Schacht
摘要
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity. We then propose specific strategies that could have the most substantial impact in improving R&D productivity.
科研通智能强力驱动
Strongly Powered by AbleSci AI